Ann: Market Update, page-2

Well..the trend continues. Still no sight in sales expanding into China. There is a risk that this becomes the norm.

In a lot of respects clover is at the mercy of the market as its produces ingredients which are inputs into the shelf product.

The business is going to have to ride this one out. I'm going to treat the investment in the same way. If the SP drops below 20c I'll look to accumulate, but its tracking to $0.006 Eps for FY15 so there is no real reason to buy right now (even with the trial results due in a few months).

Unfortunately the stock is a sell until NPAT improves. At the moment the market is obsessed with yield so any stock formally paying dividends on 6%+ yields are just going to be bid down in favour of other businesses with more reliable cashflow.